β-Lactamase-Driven Resistance to Cefiderocol in Carbapenem-Resistant Pseudomonas aeruginosa and its Reversal by Avibactam
Current Microbiology · 2026-06 · 83 (6)
DOI: 10.1007/s00284-026-04892-4 ↗Kurz gefasst
Fachartikel in der Zeitschrift Current Microbiology, online erschienen am 16.04.2026. Verfasst von Abdullah Tozluyurt. Beteiligte Einrichtung: Faculty of Medicine, Department of Medical Microbiology, School of Medicine, Hacettepe University, Ankara, Turkey. abdullahtozluyurt@hacettepe.edu.tr. Hauptthemen laut MEDLINE: Cephalosporins, Azabicyclo Compounds, Pseudomonas aeruginosa, beta-Lactamases. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 37 Literaturangaben.
Abstract (Originalsprache)
Pseudomonas aeruginosa remains one of the most formidable Gram-negative pathogens due to its extensive β-lactamase repertoire and rapidly evolving multidrug resistance. Cefiderocol, a novel siderophore cephalosporin, has emerged as a promising option against carbapenem-resistant isolates; however, its activity may be compromised in the presence of class A β-lactamases. Avibactam, a potent inhibitor of class A, class C, and selected class D β-lactamases, offers a rational strategy to restore cefiderocol efficacy. In this study, the in vitro activity of cefiderocol alone and in combination with avibactam was evaluated against 38 non-duplicate clinical carbapenem-resistant P. aeruginosa isolates collected at Hacettepe University. Antimicrobial susceptibility was assessed by disc diffusion, gradient test, and broth microdilution, while β-lactamase genes were identified by PCR and sequencing. The cefiderocol–avibactam combination was tested using a fixed avibactam concentration of 4 mg/L. Cefiderocol resistance was detected in 84.2% of isolates, with blaVEB, blaPER, and blaVIM being the most prevalent resistance determinants. Notably, the addition of avibactam produced a pronounced ≥ 8.5-fold mean reduction in cefiderocol minimum inhibitory concentrations among class A β-lactamase producers and restored susceptibility in 21 of 36 resistant isolates, whereas metallo-β-lactamase–producing strains showed minimal response. Overall, the cefiderocol–avibactam combination demonstrated significantly enhanced in vitro activity compared with cefiderocol alone (p < 0.00001), underscoring its potential clinical value as a rescue therapeutic option for infections caused by extended-spectrum β-lactamase–producing, carbapenem-resistant P. aeruginosa.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Faculty of Medicine, Department of Medical Microbiology, School of Medicine, Hacettepe University, Ankara, Turkey. abdullahtozluyurt@hacettepe.edu.tr.
Zitieren
APA
Tozluyurt, A. (2026). β-Lactamase-Driven Resistance to Cefiderocol in Carbapenem-Resistant Pseudomonas aeruginosa and its Reversal by Avibactam. Current Microbiology, 83(6). https://doi.org/10.1007/s00284-026-04892-4
Vancouver
Tozluyurt A. β-Lactamase-Driven Resistance to Cefiderocol in Carbapenem-Resistant Pseudomonas aeruginosa and its Reversal by Avibactam. Current Microbiology. 2026;83(6). doi:10.1007/s00284-026-04892-4
BibTeX
@article{Tozluyurt2026,
author = {Tozluyurt, Abdullah},
title = {β-Lactamase-Driven Resistance to Cefiderocol in Carbapenem-Resistant Pseudomonas aeruginosa and its Reversal by Avibactam},
journal = {Current Microbiology},
year = {2026},
volume = {83},
number = {6},
doi = {10.1007/s00284-026-04892-4}
}
EUVIMED